ATE465988T1 - Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirksam sind - Google Patents

Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirksam sind

Info

Publication number
ATE465988T1
ATE465988T1 AT04009193T AT04009193T ATE465988T1 AT E465988 T1 ATE465988 T1 AT E465988T1 AT 04009193 T AT04009193 T AT 04009193T AT 04009193 T AT04009193 T AT 04009193T AT E465988 T1 ATE465988 T1 AT E465988T1
Authority
AT
Austria
Prior art keywords
carnitine palmitoyl
reversible inhibitors
compounds active
palmitoyl transferase
transferase
Prior art date
Application number
AT04009193T
Other languages
German (de)
English (en)
Inventor
Fabio Giannesi
Mauro Marzi
Patrizia Minetti
Angelis Francesco De
Maria Tinti
Piero Chiodi
Arduino Arduini
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE465988T1 publication Critical patent/ATE465988T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/08—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5407—Acyclic saturated phosphonium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04009193T 1998-05-15 1999-05-11 Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirksam sind ATE465988T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98MI001075A IT1299266B1 (it) 1998-05-15 1998-05-15 Inibitori reversibili della carnitina palmitoil trasferasi

Publications (1)

Publication Number Publication Date
ATE465988T1 true ATE465988T1 (de) 2010-05-15

Family

ID=11380036

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04009193T ATE465988T1 (de) 1998-05-15 1999-05-11 Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirksam sind
AT99921135T ATE276230T1 (de) 1998-05-15 1999-05-11 Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99921135T ATE276230T1 (de) 1998-05-15 1999-05-11 Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirsam sind

Country Status (14)

Country Link
US (4) US6369073B1 (OSRAM)
EP (2) EP1077925B1 (OSRAM)
JP (1) JP5127093B2 (OSRAM)
KR (1) KR100585443B1 (OSRAM)
AT (2) ATE465988T1 (OSRAM)
AU (1) AU3847399A (OSRAM)
CA (1) CA2329930C (OSRAM)
CY (1) CY1110200T1 (OSRAM)
DE (2) DE69920208T2 (OSRAM)
DK (2) DK1077925T3 (OSRAM)
ES (2) ES2345100T3 (OSRAM)
IT (1) IT1299266B1 (OSRAM)
PT (2) PT1484313E (OSRAM)
WO (1) WO1999059957A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6822115B2 (en) * 1999-06-30 2004-11-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
IT1317885B1 (it) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti Uso di fibrati per la preparazione di un medicamento utile neltrattamento dell'insufficienza cardiaca congestizia.
ITRM20010456A1 (it) * 2001-07-26 2003-01-27 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di (r)- o (s)- amminocarnitina sale interno, dei suoi sali e dei suoi derivati.
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
ITRM20030053A1 (it) * 2003-02-10 2004-08-11 Sigma Tau Ind Farmaceuti Associazione di farmaci antidiabetici.
CA2515368A1 (en) * 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US7041286B2 (en) * 2003-07-23 2006-05-09 Nerenberg Arnold P Composition for mitigating a pernicious thrombotic event
US8314144B2 (en) 2004-02-12 2012-11-20 Defiante Farmaceutica, S.A. Compounds having antitumor activity
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006088875A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Intranasal administration of modulators of hypothalamic atp-sensitive potassium channels
ITRM20050090A1 (it) * 2005-03-02 2006-09-03 Sigma Tau Ind Farmaceutiche Riunite Spa Derivati dell'acido ammino-butanoico inibitore della cpt.
ES2342842T3 (es) * 2005-06-06 2010-07-15 F. Hoffmann-La Roche Ag Derivados de sulfamida utiles como inhibidores de la carniti-na-palmitoil-transferasa de higado (l-cpt1).
EP2046734A1 (en) * 2006-08-02 2009-04-15 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
CA2680366C (en) * 2007-03-09 2016-06-21 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
US20100210695A1 (en) * 2007-06-22 2010-08-19 Dara Biosciences, Inc. Compositions and methods for treating skin disorders
US8680282B2 (en) 2007-08-01 2014-03-25 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
US8598384B2 (en) * 2007-08-07 2013-12-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Crystalline teglicar
US20100064413A1 (en) * 2008-03-14 2010-03-18 Simply Weights, LLC Exercise clothing and accessories
RU2474573C2 (ru) 2008-04-29 2013-02-10 Ф.Хоффманн-Ля Рош Аг Производные 4-диметиламиномасляной кислоты
WO2009132979A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2309859A4 (en) * 2008-06-24 2011-09-07 Dara Biosciences Inc ENZYME INHIBITORS AND USE THEREOF
WO2010014943A2 (en) * 2008-08-01 2010-02-04 Bioxiness Pharmaceutics, Inc. Methionine analogs and methods of using same
US8178515B2 (en) * 2008-10-08 2012-05-15 Nucitec S.A. De C.V. β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof
CN109157742B (zh) 2009-08-03 2022-04-05 因卡伯实验室有限责任公司 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9492466B2 (en) 2012-06-14 2016-11-15 Nucitec S.A. De C.V. Beta-hydroxy-gamma-aminophosphonates for treating immune disorders
JP6473352B2 (ja) * 2015-03-10 2019-02-20 利幸 糸井 虚血性疾患治療薬
JP7645244B2 (ja) 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
JPS59216857A (ja) 1983-05-25 1984-12-06 Takeda Chem Ind Ltd Ｆａ―５８５９関連化合物
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
EP0127098B1 (en) 1983-05-25 1989-02-08 Takeda Chemical Industries, Ltd. Derivatives of beta-amino-gamma-trimethylammonio-butyrate, their production and use
EP0177574B1 (en) 1984-04-02 1989-12-20 Cornell Research Foundation, Inc. Aminocarnitines
IT1190163B (it) * 1986-01-13 1988-02-16 Sigma Tau Ind Farmaceuti Derivati fosforilalcanolammidici della l-carnitina e composizioni farmaceutiche che li contengono
US5196418A (en) * 1992-02-14 1993-03-23 Board Of Supervisors, Louisiana State University Agricultural & Mechanical College Hemicholinium lipids and use thereof
HUT65327A (en) 1992-06-11 1994-05-02 Sandoz Ag Process for producing phosphinyloxy-propyl-ammonium inner sact derwatives ang pharmateutical preparations containing them
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6030993A (en) * 1996-07-02 2000-02-29 Sang Sup Jew 2-hydroxypropionic acid derivative and its manufacturing method
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
IT1306162B1 (it) * 1999-06-30 2001-05-30 Sigma Tau Ind Farmaceuti Sintesi di (r) e (s)-amminocarnitina e di suoi derivati a partire daacido d e l-aspartico.
US6822115B2 (en) * 1999-06-30 2004-11-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
ITRM20010456A1 (it) * 2001-07-26 2003-01-27 Sigma Tau Ind Farmaceuti Procedimento per la preparazione di (r)- o (s)- amminocarnitina sale interno, dei suoi sali e dei suoi derivati.

Also Published As

Publication number Publication date
CA2329930A1 (en) 1999-11-25
KR20010034862A (ko) 2001-04-25
AU3847399A (en) 1999-12-06
ES2230854T3 (es) 2005-05-01
HK1033573A1 (en) 2001-09-07
WO1999059957A9 (en) 2002-06-13
IT1299266B1 (it) 2000-02-29
DE69942315D1 (de) 2010-06-10
EP1077925B1 (en) 2004-09-15
EP1484313A1 (en) 2004-12-08
DK1077925T3 (da) 2005-01-24
PT1077925E (pt) 2004-12-31
US6369073B1 (en) 2002-04-09
DE69920208T2 (de) 2005-10-20
CY1110200T1 (el) 2015-01-14
ES2345100T3 (es) 2010-09-15
US20020052348A1 (en) 2002-05-02
PT1484313E (pt) 2010-07-21
US6444701B1 (en) 2002-09-03
WO1999059957A1 (en) 1999-11-25
CA2329930C (en) 2010-02-23
USRE40861E1 (en) 2009-07-21
ITMI981075A1 (it) 1999-11-15
DK1484313T3 (da) 2010-07-19
ATE276230T1 (de) 2004-10-15
DE69920208D1 (de) 2004-10-21
KR100585443B1 (ko) 2006-06-02
EP1484313B1 (en) 2010-04-28
JP5127093B2 (ja) 2013-01-23
USRE41226E1 (en) 2010-04-13
EP1077925A1 (en) 2001-02-28
JP2003513002A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
ATE465988T1 (de) Verbindungen, die als reversible inhibitoren der carnitin palmitoyltransferase wirksam sind
PL1625150T3 (pl) Tripeptydy i ich pochodne do stosowania w kosmetyce w celu poprawy struktury skóry
DE69814375D1 (de) Fungizide trifluoromethylalkylamino-triazolopyrimidine-derivate
CA2496623A1 (en) Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
RU2000116633A (ru) Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, и способ их получения, промежуточные соединения, фармацевтическая композиция
TR199900618T2 (xx) Sib�tramin benzerlerinin diyabet geli�imini �nlemek �zere kullan�m�
DE69840296D1 (de) Phenylethylenamin-derivate
TR200200226T2 (tr) Karbonasitamidler, bu bileşikleri ihtiva eden ilaç, kullanımı ve üretimi.
EP1634874A4 (en) imidazolidine
NO20054787L (no) Indenderivater som farmasotiske midler
AU1867792A (en) Improvements in or relating to organic compounds
NO981658D0 (no) Kondensert piperidinforbindelse
NO20014099L (no) Pyridazin-3-on-derivater og medikamenter inneholdende disse
FR2822464B1 (fr) Derives biguanides et leurs applications en therapeutique
DK0937043T3 (da) Substituerede tetrahydropyridin-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse derivater
ATE90685T1 (de) Disaccharidderivate.
EP1571144A4 (en) HYDROXYALKYLATED CYCLIC DEDIAMINE COMPOUND
BR9808913A (pt) Processo para a preparação de artigos moldados compactos ou celulares semiduros á base de pur e sua estabilização, artigos moldados preparados dos mesmos, bem como seu emprego
ES2186654T3 (es) Nuevos derivados de benzodioxano imidazolinas fluoradas, su preparacion y sus aplicaciones terapeuticas.
DE60106956D1 (de) 4-cyklohexyl-1,3,2-oxazaborolidine als chirale hilfsmittel
DE60211686D1 (de) Pkb-3564-substanz mit die gefässneubildung hemmender wirkung
DK1242390T3 (da) Fremgangsmåde til fremstilling af 1,3-disubstituerede 2-nitroguanidiner
BR0303756A (pt) Processo de sìntese para a obtenção da (r)-(+)- e (s)-(-)-goniotalamina e derivados
BRPI0519179A2 (pt) derivados de triazolopirimidina
UA34108A (uk) Спосіб отримання 1,1` - (2`` - бром-2`` - хлоретенил)-біс-(5-фторурацил)-у, який має протипухлинну активність

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1484313

Country of ref document: EP